Cell cycle progression score to modify treatment decisions in prostate cancer: Results of an ongoing registry trial.

e16055 Background: Improved prognostic markers that provide individual patient risk stratification are a pressing need in prostate cancer. The cell cycle progression (CCP) test (Prolaris, Myriad Genetic Laboratories, Inc.) is a novel prognostic assay that has been validated in multiple cohorts and provides accurate risk of prostate cancer-specific disease progression and disease specific mortality risk when combined with standard clinicopathologic parameters. This study evaluated clinicians’ judgment regarding the clinical utility of the CCP test in a prospective registry. Methods: Clinicians ordering the CCP test commercially were asked to complete a survey regarding their treatment recommendations before and after they received the CCP test result. In addition, clinicians were asked how influential the CCP test result was in making therapeutic decisions on a five point scale (0=none, 4=very high). Results: Currently, 331 patients have been enrolled and 150 clinicians have completed surveys on the influe...